Research ArticleCancer

Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events

See allHide authors and affiliations

Science Translational Medicine  08 Nov 2017:
Vol. 9, Issue 415, eaan0401
DOI: 10.1126/scitranslmed.aan0401

Article Information

vol. 9 no. 415

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication June 5, 2017
  • Accepted for publication September 27, 2017
  • .

Author Information

  1. Jun Ishihara1,2,
  2. Kazuto Fukunaga1,2,3,*,
  3. Ako Ishihara1,*,
  4. Hans M. Larsson2,
  5. Lambert Potin1,2,
  6. Peyman Hosseinchi1,
  7. Gabriele Galliverti2,
  8. Melody A. Swartz1,2,4,5 and
  9. Jeffrey A. Hubbell1,2,5,
  1. 1Institute for Molecular Engineering, University of Chicago, Chicago, IL 60637, USA.
  2. 2Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland.
  3. 3Department of Bioengineering, Tokyo Institute of Technology, 226-8501 Yokohama, Kanagawa, Japan.
  4. 4Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland.
  5. 5Institute of Chemical Sciences and Engineering, School of Basic Sciences, Ecole Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland.
  1. Corresponding author. Email: jhubbell{at}uchicago.edu
    • * These authors contributed equally to this work.

    Altmetric

    Article usage

    Article usage: November 2017 to October 2019

    AbstractFullPdf
    Nov 2017104395331293
    Dec 201784564176
    Jan 201852444131
    Feb 201852954102
    Mar 20183274078
    Apr 201839754114
    May 20183073864
    Jun 20182232970
    Jul 20181262943
    Aug 2018846349
    Sep 20181027339
    Oct 20181397168
    Nov 201838156101
    Dec 2018015282
    Jan 201913167116
    Feb 20192114984
    Mar 201929194114
    Apr 201936295181
    May 201916220193
    Jun 20192018495
    Jul 201914144125
    Aug 20191513893
    Sep 20192111586
    Oct 2019143734

    Navigate This Article